PK of Lidocaine/Tetracaine and PD Derived From a New Topical Formulation for Treatment of Neuropathic Pain.

Launched by PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE · Dec 13, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new topical treatment for neuropathic pain, specifically focusing on a combination of lidocaine and tetracaine. Neuropathic pain can occur after conditions like shingles (which can lead to post-herpetic neuralgia) or from other nerve-related issues, and it often requires ongoing treatment. Traditional medications like certain antidepressants and opioids can have serious side effects that make patients feel worse, so researchers are exploring a topical option that may be safer and more effective. The trial aims to measure how much lidocaine enters the bloodstream when using a new cream that contains 23% lidocaine and 7% tetracaine.

To participate in this trial, individuals aged 18 and older who have specific types of neuropathic pain, such as trigeminal neuralgia, postherpetic neuralgia, diabetic neuropathy, and several others, may be eligible. However, those currently receiving intravenous lidocaine or other treatments that could interfere with the study will not qualify. Participants can expect to apply the topical treatment and be monitored for its effects and safety. This research is important because it could lead to better pain management options that improve the quality of life for those suffering from chronic nerve pain.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Trigeminal neuralgia
• • Postherpetic neuralgia
• • Diabetic neuropathy
• • Chronic postoperative pain
• • Complex regional pain syndrome
• • HIV neuropathy
• • Peripheral neuropathy
• Exclusion Criteria:
• • Intravenous lidocaine and/or other treatment interfering with the protocol